SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that it will host an investor event to discuss expected corporate and product milestones in 2018. The event is scheduled to take place on Tuesday, January 9, at 7 a.m. PT (10 a.m. ET) and will be simultaneously webcast.
Portola will provide clinical, regulatory and manufacturing updates on the Company’s first FDA-approved product, betrixaban, and its two investigational hematologic compounds – the anticoagulant reversal agent andexanet alfa and the oral, dual Syk/JAK kinase inhibitor cerdulatinib.
To access the live investor webcast on Tuesday, January 9 at 7 a.m. PT (10 a.m. ET), go to the Investor Relations section of the company’s website at http://investors.portola.com. A replay will be available for 30 days.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Portola Pharmaceuticals, Inc.